Today Aker BioMarine employees were informed of the Company’s intention to make changes to Group financial reporting and legal entity structure. The “Ingredients” and “Brands” financial reporting segments will be deconsolidated into:
1. Feed Ingredients including Qrill Aqua and Pet, harvesting operations and Uruguay distribution
2. Human Health Ingredients including Superba, Lysoveta and Houston manufacturing
3. Consumer Health Products including Lang Pharma Nutrition, a premium private label innovation and sales business in the US
4. Emerging Businesses including Epion Brands (Kori krill oil), Aion AS and Understory Protein
The new financial reporting and legal entity structure is meant to result in better alignment between company strategy, operations, and financials, and to improve transparency of business segments’ earnings development.
The Company will keep current external reporting structure through 2023, with the new structures expected to be in place Q1 2024. Additional information will be provided at the Q2 presentation on 14 July 2023.
For further information, please contact
Christopher Robin Vinter, Investor Relations
Mobile: +47 911 60 820
Email: Christopher.vinter@akerbiomarine.com
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.